OPKO Health (NASDAQ:OPK) Presents at 43rd Annual J.P. Morgan Healthcare Conference

OPKO Health, Inc. recently announced that key members of its management team participated in investor meetings at the 43rd Annual J.P. Morgan Healthcare Conference. The company disclosed this information through a Form 8-K filing on January 15, 2025.

The company’s presentation materials from the conference have been made available as Exhibit 99.1 in the Current Report on Form 8-K. These materials can also be accessed on OPKO Health’s official website under Investor Relations. It is important to note that the information provided on the company’s website is not considered part of the formal report.

Within the Form 8-K, OPKO Health stated that the details shared during the event are not to be regarded as “filed” under the Securities Exchange Act of 1934. Furthermore, the content presented during the conference and included in Exhibit 99.1 is not to be integrated by reference in any future filings under the Securities Act of 1933 or the Securities Exchange Act of 1934, unless explicitly indicated within those filings.

In addition to the aforementioned disclosure, the Form 8-K also included details under Item 9.01, pertaining to Financial Statements and Exhibits. The company furnished Exhibit 99.1, which contains OPKO Health, Inc.’s Presentation Materials, and Exhibit 104, covering the Interactive Data File embedded within the Inline XBRL document.

As per the signature section of the filing, OPKO Health, Inc.’s Executive Vice President – Administration, Steven D. Rubin, signed the report on behalf of the company on January 15, 2025, in compliance with the Securities Exchange Act of 1934.

Overall, by actively engaging in investor meetings at the prestigious J.P. Morgan Healthcare Conference, OPKO Health continues to strengthen its presence and communication within the healthcare and investment communities.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read OPKO Health’s 8K filing here.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.